Skip to main content
Traws Pharma, Inc. logo

Traws Pharma, Inc. — Investor Relations & Filings

Ticker · TRAW ISIN · US68232V8845 LEI · 549300BRAR7BTG2PIY51 US Manufacturing
Open in API
Filings indexed 932 across all filing types
Latest filing 2026-05-29 Annual Report
Country US United States of America
Listing US TRAW

About Traws Pharma, Inc.

https://www.trawspharma.com/

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel oral small-molecule therapies for respiratory viral diseases. The company focuses on advancing investigational antiviral agents with potent activity against difficult-to-treat or resistant virus strains. Its pipeline includes two lead candidates: ratutrelvir, a ritonavir-independent antiviral targeting the Main protease (Mpro) for the treatment of COVID-19 and Long COVID, and tivoxavir marboxil, a single-dose antiviral targeting the influenza cap-dependent endonuclease (CEN) for the treatment and prevention of bird flu and seasonal influenza. The company aims to develop safe product candidates with simple dosing regimens.

Recent filings

Filing Released Lang Actions
ARS
Annual Report
2026-05-29 English
DEFA14A
Proxy Solicitation & Information Statement
2026-05-29 English
DEF 14A
Proxy Solicitation & Information Statement
2026-05-29 English
FORM 8-K
Regulatory Filings Classification · 74% confidence The document is a Form 8-K current report filing with the SEC, consisting of Regulation FD Disclosure (press release) and exhibits. It does not contain substantive financial statements nor announce dividends, management changes, or other specific events like M&A, earnings, or share issues. It is a general SEC filing of miscellaneous information (press release) and thus falls under the fallback category for general regulatory filings.
2026-05-27 English
FORM 8-K
Regulatory Filings
2026-05-26 English
424B5
Share Issue/Capital Change Classification · 82% confidence The document is an SEC prospectus supplement (Rule 424(b)(5)) amending shelf registration and the at-the-market (ATM) offering agreement to update maximum aggregate gross sales of newly issued common stock. It is clearly an announcement of new share issuance under the ATM program, not a financial result, report, or management call. Therefore, it fits the “Share Issue/Capital Change” category.
2026-05-22 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.